David Faleck, MD

About Me

I am a gastroenterologist who specializes in caring for people with inflammatory bowel disease (IBD). I have a particular interest in addressing the challenges faced by people managing both IBD and cancer. I am also interested in the gastrointestinal (GI) side effects of immunotherapies, which can cause IBD-like illnesses in people undergoing treatment.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

People with IBD may be at an increased risk for certain GI cancers. Some of the medications used to treat IBD are associated with a small increased risk of certain non-GI cancers. People with IBD who have been diagnosed with cancer are often concerned about the chance that these therapies might make their cancer more aggressive or more likely to return. My practice is dedicated to exploring treatment options with patients. I weigh the risks and benefits of various therapies and monitor my patients closely for possible complications.

I work with nurses, colorectal surgeons, primary care physicians, nutritionists, mental health professionals, and other specialists to optimize care for my patients. I place a special emphasis on preventive care to reduce the risk of IBD-related infections and other complications. I also stress screening for GI and non-GI cancers. For high-risk patients having a colonoscopy, I use a technique called chromoendoscopy to improve the chances of seeing precancerous changes in the colon.

Caring for people with IBD is a rapidly evolving field that has seen remarkable progress in recent decades. There has been a major shift in the standards of care. The aim now is to heal patients both inside (through treating intestinal inflammation) and out (by targeting their most bothersome symptoms). Recently approved medications and a promising pipeline of new therapies will hopefully benefit patients tremendously.

I am actively involved in clinical research. I am currently a co-investigator on a study evaluating autologous stem cell transplantation for people with aggressive Crohn’s disease that does not respond to currently approved treatments. I am also involved in numerous studies assessing the effectiveness and safety of newly approved biologic therapies for IBD.

GI conditions, and IBD in particular, often have a profound impact on a person’s quality of life. Because of their symptoms, people with IBD may even fear leaving the house and participating in daily activities. I strive to reassure my patients that with appropriate treatment they can achieve tremendous improvement in their symptoms and regain a meaningful quality of life.

After I meet with patients, I hope they walk away with a sense that I empathize with their condition and have the knowledge and tools to help alleviate their symptoms. I firmly believe that a strong partnership between patients and doctors provides for the best possible outcomes. Together, we can treat their symptoms and disease and improve their quality of life.

Outside of work, I enjoy traveling, cooking, and spending time with my family.

  • Clinical Expertise: Crohn’s Disease; Ulcerative Colitis; GI Complications of Immunotherapy; Colorectal Cancer; Colon Dysplasia Surveillance; Colonoscopy; Polypectomy; Chromoendoscopy; Upper Gastrointestinal Endoscopy; Percutaneous Endoscopic Gastrostomy
  • Awards and Honors: Alpha Omega Alpha Honor Medical Society, Albert Einstein College of Medicine (2011); Golding Research Tuition Scholarship, Albert Einstein College of Medicine (2008-2012); Phi Beta Kappa Honor Society, University of Pennsylvania (2007)
  • Languages Spoken: English; Hebrew; Spanish
  • Education: MD, Albert Einstein College of Medicine
  • Residencies: Internal Medicine – Columbia University Medical Center/New York-Presbyterian
  • Fellowships: Gastroenterology – Mount Sinai Hospital
  • Board Certifications: Internal Medicine

Publications

Visit PubMed for a full listing of David Faleck’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more Arrow rightAn icon showing an arrow pointing to the right.

Insurance

Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.